ARTELO BIOSCIENCES, INC. Financing Cash Flow
ARTELO BIOSCIENCES, INC. (ARTL) reported Financing Cash Flow of $9.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.06M, a 158.59% decline year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $10.86M.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.61M, a 2719.30% increase year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.44M.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2022 was $0.00.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2021 was $14.11M, a 612.37% increase from fiscal 2020.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2020 was $1.98M, a 76.35% decline from fiscal 2019.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2019 was $8.38M, a 503.36% increase from fiscal 2018.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.80M 10-Q · filed 2026-08-12 | $11.40M derived: sum of 3 quarters · filed 2026-08-12 | $14.85M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $10.86M 10-Q · filed 2026-05-14 | $12.47M derived: sum of 2 quarters · filed 2026-05-14 | $15.91M derived: sum of 3 quarters · filed 2026-05-14 | $17.73M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | $1.61M derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.05M derived: sum of 2 quarters · filed 2026-03-17 | $6.87M derived: sum of 3 quarters · filed 2026-08-12 | $6.87M 8-K · filed 2026-03-17 | |||
| 2025-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.26M derived: sum of 2 quarters · filed 2026-08-12 | $5.26M 10-Q · filed 2025-11-12 | $5.32M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.82M 10-Q · filed 2026-08-12 | $1.87M derived: sum of 3 quarters · filed 2026-08-12 | $1.87M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $57.00K derived: sum of 2 quarters · filed 2026-05-14 | $57.00K derived: sum of 3 quarters · filed 2026-05-14 | $57.00K derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $57.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $57.00K derived: sum of 2 quarters · filed 2026-03-17 | $57.00K derived: sum of 3 quarters · filed 2026-03-17 | $112.00K 8-K · filed 2026-03-17 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $55.00K 10-Q · filed 2025-11-12 | $87.00K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $55.00K 10-Q · filed 2025-08-13 | $87.00K derived: sum of 3 quarters · filed 2025-08-13 | $622.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $55.00K 8-K · filed 2025-07-11 | $87.00K derived: sum of 2 quarters · filed 2025-07-11 | $622.00K derived: sum of 3 quarters · filed 2025-07-11 | $622.00K derived: sum of 4 quarters · filed 2025-07-11 | |||
| 2023-12-31 | $32.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $567.00K derived: sum of 2 quarters · filed 2025-07-11 | $567.00K derived: sum of 3 quarters · filed 2025-07-11 | $567.00K 8-K · filed 2025-07-11 | |||
| 2023-09-30 | $535.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $535.00K derived: sum of 2 quarters · filed 2024-11-12 | $535.00K 10-Q · filed 2024-11-12 | $669.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $134.00K derived: sum of 3 quarters · filed 2024-08-13 | $134.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $134.00K derived: sum of 2 quarters · filed 2024-05-13 | $134.00K derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $134.00K derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$134.00K derived: sum of 2 quarters · filed 2023-11-13 | -$134.00K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$134.00K 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | $18.26M 10-K · filed 2023-03-31 | ||||||
| 2021-11-30 | $18.26M 10-Q · filed 2022-01-12 | ||||||
| 2021-09-30 | $397.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $7.61M 10-Q · filed 2022-11-08 | |||||
| 2021-08-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $14.11M 10-K · filed 2023-03-31 | |||||
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $7.21M 10-Q · filed 2022-08-09 | |||||
| 2021-05-31 | $617.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-12 | $12.52M 10-Q · filed 2021-07-12 | |||||
| 2021-03-31 | $6.01M 10-Q · filed 2022-05-12 | ||||||
| 2021-02-28 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-13 | $11.90M 10-Q · filed 2021-04-13 | $13.61M derived: sum of 3 quarters · filed 2022-03-21 | $13.89M derived: sum of 4 quarters · filed 2022-03-21 | |||
| 2020-12-31 | $6.58M 10-KT · filed 2022-03-21 | ||||||
| 2020-11-30 | $6.58M 10-Q · filed 2022-01-12 | $6.58M 10-Q · filed 2021-01-14 | $8.29M derived: sum of 2 quarters · filed 2022-03-21 | $8.57M derived: sum of 3 quarters · filed 2022-03-21 | $8.57M derived: sum of 4 quarters · filed 2022-03-21 | ||
| 2020-08-31 | $1.71M derived: 10-KT 12 month − 10-Q 9 month · filed 2022-03-21 | $1.99M derived: sum of 2 quarters · filed 2022-03-21 | $1.99M derived: sum of 3 quarters · filed 2022-03-21 | $1.98M 10-KT · filed 2022-03-21 | $1.98M 10-K · filed 2020-11-04 | ||
| 2020-05-31 | $282.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-12 | $284.75K derived: sum of 2 quarters · filed 2021-07-12 | $270.77K 10-Q · filed 2021-07-12 | $6.97M derived: sum of 4 quarters · filed 2021-07-12 | |||
| 2020-02-29 | $2.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-13 | -$11.89K 10-Q · filed 2021-04-13 | $6.69M derived: sum of 3 quarters · filed 2021-04-13 | $7.10M derived: sum of 4 quarters · filed 2021-04-13 | |||
| 2019-11-30 | -$13.97K 10-Q · filed 2021-01-14 | $6.68M derived: sum of 2 quarters · filed 2021-01-14 | $7.10M derived: sum of 3 quarters · filed 2021-01-14 | $8.19M derived: sum of 4 quarters · filed 2021-01-14 | |||
| 2019-08-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-04 | $7.12M derived: sum of 2 quarters · filed 2020-11-04 | $8.20M derived: sum of 3 quarters · filed 2020-11-04 | $8.38M 10-K · filed 2020-11-04 | |||
| 2019-05-31 | $419.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-07-13 | $1.51M derived: sum of 2 quarters · filed 2020-07-13 | $1.68M 10-Q · filed 2020-07-13 | $2.21M derived: sum of 4 quarters · filed 2020-07-13 | |||
| 2019-02-28 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-13 | $1.26M 10-Q · filed 2020-04-13 | $1.79M derived: sum of 3 quarters · filed 2020-04-13 | $2.06M derived: sum of 4 quarters · filed 2020-04-13 | |||
| 2018-11-30 | $173.90K 10-Q · filed 2020-01-14 | $699.70K derived: sum of 2 quarters · filed 2020-01-14 | $969.48K derived: sum of 3 quarters · filed 2020-01-14 | $1.55M derived: sum of 4 quarters · filed 2020-01-14 | |||
| 2018-08-31 | $525.79K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-18 | $795.57K derived: sum of 2 quarters · filed 2019-12-18 | $1.38M derived: sum of 3 quarters · filed 2019-12-18 | $1.39M 10-K/A · filed 2019-12-18 | |||
| 2018-05-31 | $269.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-15 | $851.21K derived: sum of 2 quarters · filed 2019-07-15 | $862.66K 10-Q · filed 2019-07-15 | $1.36M derived: sum of 4 quarters · filed 2019-07-15 | |||
| 2018-02-28 | $581.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-15 | $592.88K 10-Q · filed 2019-04-15 | $1.10M derived: sum of 3 quarters · filed 2019-04-15 | ||||
| 2017-11-30 | $11.45K 10-Q · filed 2019-01-14 | $513.68K derived: sum of 2 quarters · filed 2019-01-14 | |||||
| 2017-08-31 | $502.24K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $785.35K 10-K · filed 2018-11-29 | |||||
| 2017-05-31 | $283.11K 10-Q · filed 2018-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |